The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
The latest report by IMARC, titled “ Cholera Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023 -2028
” " the global cholera vaccines market reached a value of US$ 4.9 Million in 2022.
Cholera is an acute intestinal disease that is generally caused by the consumption of contaminated water and food. It is spread by the Vibrio Cholerae bacteria that leads to pain in the abdomen, diarrhea, nausea, vomiting and water-electrolyte imbalance. Cholera vaccines are effective in stimulating the production of antibodies that aid in preventing the disease among individuals. Widely prepared using the live cholera-causing bacteria to aid in developing immunity against the same, these vaccines are directly injected intramuscularly or intradermally in the body.
Request Free Sample Report: https://www.imarcgroup.com/cholera-vaccines-market/requestsample
The global market is primarily driven by the escalating prevalence of cholera among the masses. This can be attributed to the poor sanitation and hygiene conditions in rural and geographically extended areas. Moreover, the rising awareness regarding the availability of cholera vaccines among the masses has propelled the product demand. In line with this, numerous initiatives undertaken by several government agencies and non-government organizations (NGOs) across multiple countries for conducting immunization programs are providing a boost to the demand for cholera vaccines.
Along with this, the increasing investments and funding by public and private agencies for conducting extensive research and development (R&D) activities are favorably impacting the market. Other factors, including the expanding healthcare expenditure, a considerable increase in water pollution levels, and the rising number of research laboratories and diagnosis centers, are also positively influencing the market growth. On account of the aforementioned factors, the market is anticipated to reach a value of US$ 9.2 Million by 2028.
Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).
Market Summary:
Breakup by Vaccine Type:
• Whole Cell V. Cholerae O1 with Recombinant B-Subunit
• Killed Oral O1 and O139
Breakup by Product:
• Dukoral
• Shanchol
• Vaxchora
• Euvichol and Euvichol-Plus
• Others
Breakup by End User:
• Hospitals and Clinics
• Research and Academic Laboratories
• Others
Breakup by Region:
• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
Competitive Landscape with Key Players:
• Astellas Pharma Inc
• Celldex Therapeutics Inc. (Avant Immunotherapeutics Inc.)
• Emergent BioSolutions Inc.
• Eubiologics Co. Ltd.
• Johnson & Johnson
• Merck & Co. Inc
• Pfizer Inc.
• PharmaChoice Canada Inc
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Valneva SE.
We are the trusted business partners to the world's leading corporates, governments, and institutions
We are the trusted business partners to the world's leading corporates, governments, and institutions
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
